Clinical Efficacy and Safety of Sitafloxacin 200 mg Once Daily for Refractory Genitourinary Tract Infections

Takehiro Iwata; Takuya Sadahira; Yuki Maruyama; Takanori Sekito; Kasumi Yoshinaga; Shogo Watari; Kentaro Nagao; Tatsushi Kawada; Yusuke Tominaga; Shingo Nishimura; Atsushi Takamoto; Tomoko Sako; Kohei Edamura; Yasuyuki Kobayashi; Motoo Araki; Ayano Ishii; Masami Watanabe; Toyohiko Watanabe; Yasutomo Nasu; Koichiro Wada

Clinical Efficacy and Safety of Sitafloxacin 200 mg Once Daily for Refractory Genitourinary Tract Infections

Takehiro Iwata, Takuya Sadahira, Yuki Maruyama, Takanori Sekito, Kasumi Yoshinaga, Shogo Watari, Kentaro Nagao, Tatsushi Kawada, Yusuke Tominaga, Shingo Nishimura, Atsushi Takamoto, Tomoko Sako, Kohei Edamura, Yasuyuki Kobayashi, Motoo Araki, Ayano Ishii, Masami Watanabe, Toyohiko Watanabe, Yasutomo Nasu, Koichiro Wada

University Hospital

Research output: Contribution to journal › Article › peer-review

Abstract

The aim of this ongoing trial is to evaluate the clinical efficacy and safety of sitafloxacin (STFX) 200 mg once daily (QD) for 7 days in patients with refractory genitourinary tract infections, which include recurrent or complicated cystitis, complicated pyelonephritis, bacterial prostatitis, and epididymitis. The primary endpoint is the microbiological efficacy at 5-9 days after the last administration of STFX. Recruitment began in February 2021, and the target total sample size is 92 participants.

Original language	English
Pages (from-to)	763-766
Number of pages	4
Journal	Acta medica Okayama
Volume	75
Issue number	6
Publication status	Published - 2021

Keywords

Extended-spectrum beta-lactamase
Fluoroquinolone resistance
Genitourinary tract infections

ASJC Scopus subject areas

Biochemistry, Genetics and Molecular Biology(all)

Cite this

Iwata, T., Sadahira, T., Maruyama, Y., Sekito, T., Yoshinaga, K., Watari, S., Nagao, K., Kawada, T., Tominaga, Y., Nishimura, S., Takamoto, A., Sako, T., Edamura, K., Kobayashi, Y., Araki, M., Ishii, A., Watanabe, M., Watanabe, T., Nasu, Y., & Wada, K. (2021). Clinical Efficacy and Safety of Sitafloxacin 200 mg Once Daily for Refractory Genitourinary Tract Infections. Acta medica Okayama, 75(6), 763-766.

Iwata, T , Sadahira, T , Maruyama, Y, Sekito, T, Yoshinaga, K, Watari, S, Nagao, K, Kawada, T, Tominaga, Y, Nishimura, S, Takamoto, A, Sako, T, Edamura, K , Kobayashi, Y , Araki, M , Ishii, A , Watanabe, M , Watanabe, T , Nasu, Y & Wada, K 2021, 'Clinical Efficacy and Safety of Sitafloxacin 200 mg Once Daily for Refractory Genitourinary Tract Infections', Acta medica Okayama, vol. 75, no. 6, pp. 763-766.

@article{34fb0d3e45104959ac73cb224361d0b9,

title = "Clinical Efficacy and Safety of Sitafloxacin 200 mg Once Daily for Refractory Genitourinary Tract Infections",

abstract = "The aim of this ongoing trial is to evaluate the clinical efficacy and safety of sitafloxacin (STFX) 200 mg once daily (QD) for 7 days in patients with refractory genitourinary tract infections, which include recurrent or complicated cystitis, complicated pyelonephritis, bacterial prostatitis, and epididymitis. The primary endpoint is the microbiological efficacy at 5-9 days after the last administration of STFX. Recruitment began in February 2021, and the target total sample size is 92 participants.",

keywords = "Extended-spectrum beta-lactamase, Fluoroquinolone resistance, Genitourinary tract infections",

author = "Takehiro Iwata and Takuya Sadahira and Yuki Maruyama and Takanori Sekito and Kasumi Yoshinaga and Shogo Watari and Kentaro Nagao and Tatsushi Kawada and Yusuke Tominaga and Shingo Nishimura and Atsushi Takamoto and Tomoko Sako and Kohei Edamura and Yasuyuki Kobayashi and Motoo Araki and Ayano Ishii and Masami Watanabe and Toyohiko Watanabe and Yasutomo Nasu and Koichiro Wada",

year = "2021",

language = "English",

volume = "75",

pages = "763--766",

journal = "Acta Medica Okayama",

issn = "0386-300X",

publisher = "Okayama University",

number = "6",

}

TY - JOUR

T1 - Clinical Efficacy and Safety of Sitafloxacin 200 mg Once Daily for Refractory Genitourinary Tract Infections

AU - Iwata, Takehiro

AU - Sadahira, Takuya

AU - Maruyama, Yuki

AU - Sekito, Takanori

AU - Yoshinaga, Kasumi

AU - Watari, Shogo

AU - Nagao, Kentaro

AU - Kawada, Tatsushi

AU - Tominaga, Yusuke

AU - Nishimura, Shingo

AU - Takamoto, Atsushi

AU - Sako, Tomoko

AU - Edamura, Kohei

AU - Kobayashi, Yasuyuki

AU - Araki, Motoo

AU - Ishii, Ayano

AU - Watanabe, Masami

AU - Watanabe, Toyohiko

AU - Nasu, Yasutomo

AU - Wada, Koichiro

PY - 2021

Y1 - 2021

N2 - The aim of this ongoing trial is to evaluate the clinical efficacy and safety of sitafloxacin (STFX) 200 mg once daily (QD) for 7 days in patients with refractory genitourinary tract infections, which include recurrent or complicated cystitis, complicated pyelonephritis, bacterial prostatitis, and epididymitis. The primary endpoint is the microbiological efficacy at 5-9 days after the last administration of STFX. Recruitment began in February 2021, and the target total sample size is 92 participants.

AB - The aim of this ongoing trial is to evaluate the clinical efficacy and safety of sitafloxacin (STFX) 200 mg once daily (QD) for 7 days in patients with refractory genitourinary tract infections, which include recurrent or complicated cystitis, complicated pyelonephritis, bacterial prostatitis, and epididymitis. The primary endpoint is the microbiological efficacy at 5-9 days after the last administration of STFX. Recruitment began in February 2021, and the target total sample size is 92 participants.

KW - Extended-spectrum beta-lactamase

KW - Fluoroquinolone resistance

KW - Genitourinary tract infections

UR - http://www.scopus.com/inward/record.url?scp=85122908536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85122908536&partnerID=8YFLogxK

M3 - Article

C2 - 34955548

AN - SCOPUS:85122908536

SN - 0386-300X

VL - 75

SP - 763

EP - 766

JO - Acta Medica Okayama

JF - Acta Medica Okayama

IS - 6

ER -

Clinical Efficacy and Safety of Sitafloxacin 200 mg Once Daily for Refractory Genitourinary Tract Infections

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this